Amgen Inc. (NASDAQ:AMGN) Stock Position Decreased by PSI Advisors LLC

PSI Advisors LLC lessened its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 31.8% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 384 shares of the medical research company’s stock after selling 179 shares during the period. PSI Advisors LLC’s holdings in Amgen were worth $111,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of the business. Southland Equity Partners LLC increased its holdings in shares of Amgen by 2.3% during the 4th quarter. Southland Equity Partners LLC now owns 1,538 shares of the medical research company’s stock worth $443,000 after purchasing an additional 34 shares during the period. Acropolis Investment Management LLC boosted its position in shares of Amgen by 3.5% during the 4th quarter. Acropolis Investment Management LLC now owns 999 shares of the medical research company’s stock valued at $288,000 after acquiring an additional 34 shares in the last quarter. Opal Wealth Advisors LLC boosted its position in shares of Amgen by 1.9% during the 4th quarter. Opal Wealth Advisors LLC now owns 1,868 shares of the medical research company’s stock valued at $538,000 after acquiring an additional 34 shares in the last quarter. Marino Stram & Associates LLC boosted its position in shares of Amgen by 0.7% during the 4th quarter. Marino Stram & Associates LLC now owns 4,626 shares of the medical research company’s stock valued at $1,332,000 after acquiring an additional 34 shares in the last quarter. Finally, FORVIS Wealth Advisors LLC boosted its position in shares of Amgen by 1.4% during the 4th quarter. FORVIS Wealth Advisors LLC now owns 2,578 shares of the medical research company’s stock valued at $743,000 after acquiring an additional 35 shares in the last quarter. Institutional investors own 76.50% of the company’s stock.

Amgen Trading Up 2.4 %

Shares of NASDAQ AMGN opened at $268.93 on Monday. Amgen Inc. has a 1-year low of $211.71 and a 1-year high of $329.72. The company has a market cap of $144.25 billion, a PE ratio of 21.53, a P/E/G ratio of 2.50 and a beta of 0.58. The company has a current ratio of 1.65, a quick ratio of 1.13 and a debt-to-equity ratio of 10.14. The company has a 50-day moving average of $276.90 and a two-hundred day moving average of $281.51.

Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, February 6th. The medical research company reported $4.71 earnings per share for the quarter, topping analysts’ consensus estimates of $4.66 by $0.05. Amgen had a net margin of 23.83% and a return on equity of 154.27%. The company had revenue of $8.20 billion during the quarter, compared to the consensus estimate of $8.13 billion. During the same period in the previous year, the firm posted $4.09 earnings per share. The company’s revenue was up 19.8% on a year-over-year basis. As a group, equities analysts expect that Amgen Inc. will post 19.45 earnings per share for the current fiscal year.

Amgen Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 7th. Investors of record on Friday, May 17th will be paid a dividend of $2.25 per share. This represents a $9.00 dividend on an annualized basis and a dividend yield of 3.35%. The ex-dividend date of this dividend is Thursday, May 16th. Amgen’s dividend payout ratio (DPR) is 72.06%.

Analyst Ratings Changes

Several analysts have recently weighed in on the stock. Truist Financial reiterated a “buy” rating and set a $320.00 target price on shares of Amgen in a research report on Friday, April 12th. The Goldman Sachs Group lifted their target price on shares of Amgen from $313.00 to $350.00 and gave the company a “buy” rating in a research report on Wednesday, February 7th. SVB Leerink lowered shares of Amgen from an “outperform” rating to a “market perform” rating and decreased their target price for the company from $324.00 to $318.00 in a research report on Wednesday, February 7th. Oppenheimer reiterated an “outperform” rating and set a $350.00 target price on shares of Amgen in a research report on Thursday, February 1st. Finally, Leerink Partnrs lowered shares of Amgen from an “outperform” rating to a “market perform” rating in a research report on Wednesday, February 7th. Ten analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $296.95.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.